Updates on Multiple Myeloma: What’s New in Risk Stratification, Treatment, and Prognosis
Multiple myeloma accounts for 10% of hematological malignancy and 1% of all cancer. It manifests with anemia, hypercalcemia, renal failure, and bone lesions, with the latter being the most common cause of morbidity. Over the last two decades, many advances were achieved in different aspects of the d...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2022
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/83482 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: Updates on Multiple Myeloma: What’s New in Risk Stratification, Treatment, and Prognosis
- Treatment Approaches of Multiple Myeloma
- Introductory Chapter: Update on Multiple Myeloma
- Treatment of Multiple Myeloma in the First Relapse
- Proteasome Inhibitors in the Treatment of Multiple Myeloma
- Treatment of Patients with Newly-Diagnosed Multiple Myeloma
- Treatment and Disease-related Complications in Multiple Myeloma